Table 1.

Characteristics of included studies.

Study	Year	Sample Size		Age		Sex (male/female)		Other Eye Medication	Treatment Duration	Anesthesia for Schirmer Test
		PUFA	Control	PUFA	Control	PUFA	Control
Asbell et al. [22]	2018	349	186	58.3 ± 13.5	57.5 ± 12.6	65/284	36/150	Allowed	12 months	Yes
Barabino et al. [13]	2003	13	13	63.4 ± 8.2	54.3 ± 11.3	4/9	3/10	Limited	1.5months	NR
Bhargava et al. [14]	2013	264	254	38.82±4.12	40.06 ± 6.76	Total:	254/268	Limited	3 months	Yes
Brignole-Baudouin et al. [23]	2011	58	63	60 ± 11.75	59.7 ± 11.95	1/57	3/60	Allowed	3 months	NR
Chinnery et al. [15]	2017	8	4	42 ± 7 a	46 ± 10 a	2/6	1/3	Limited	3 months	NR
Creuzo-Garcher et al. [16]	2011	90	91	61.28 ± 12.15	61.79 ± 11.64	8/82	7/84	Allowed	6 months	NR
Creuzot-Garcher et al. [28]	2006	36	35	59.7 ± 14.7	61.1 ± 11.1	2/34	1/34	Limited	6 months	No
Deinema et al. [17]	2017	37	17	Total:	42.51	Total:	18/36	Limited	3 months	Yes
Kangari et al. [18]	2013	33	31	60.6 ± 8.7	61.8 ± 8	15/18	11/20	Limited	1 month	No
Kawakita et al. [19]	2013	15	11	52.5 ± 2.5 a	51.9 ± 2.2 a	5/10	1/10	Limited	4 months	No
Larmo et al. [24]	2010	52	48	45 ± 18	46 ± 17	8/44	7/41	Allowed	3 months	No
Sheppard et al. [21]	2013	19	19	62 ± 1 a	61 ± 2 a	0/19	0/19	Limited	6 months	NR
Wojtowicz et al. [25]	2011	21	15	Total:	61	Total:	20/16	Limited	3 months	No

^a Standard error. PUFA, polyunsaturated fatty acid. NR, not reported.